Melanoma medical therapy

Jump to: navigation, search

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Serge Korjian M.D.; Yazan Daaboul, M.D.

Melanoma Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Melanoma from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X-ray

Echocardiography and Ultrasound

CT scan

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Melanoma medical therapy On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Melanoma medical therapy

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Melanoma medical therapy

CDC on Melanoma medical therapy

Melanoma medical therapy in the news

Blogs on Melanoma medical therapy

Directions to Hospitals Treating Melanoma

Risk calculators and risk factors for Melanoma medical therapy

Overview

Chemotherapy is indicated for high risk melanomas (stages IIB-IV) as adjuvant therapy and for metastatic disease as first-line therapy. Several single agent and combination regimens have been studied, all with modest impact on survival. All current guidelines still recommend enrollment in clinical trials over current available regimens for patients with metastatic disease. Interferon therapy is the only regimen recommended for adjuvant therapy.

Medical Therapy

  • Surgery is the predominant therapy for melanoma.a

Chemotherapy regimens

Adjuvant therapy[1]

  1. Interferon alfa-2a (Roferon-A)
  2. Interferon alfa-2b (Intron-A)
  3. Peginterferon alfa-2b (Sylatron)

Metastatic or unresectable melanoma[1]
Either a single agent chemotherapy OR a combination chemotherapy is recommended for metastatic or unresectable melanoma.

  • Single Agent Chemotherapy
  1. Dabrafenib (Tafinlar)
  2. Dacarbazine (DTIC)
  3. Docetaxel (Taxotere)
  4. Interleukin-2 (high dose or maintenance biotherapy)
  5. Imatinib (Gleevec)
  6. Ipilimumab (Yervoy)
  7. Nivolumab (Opdivo)
  8. Paclitaxel (Taxol)
  9. Pembrolizumab (Keytruda)
  10. Temozolomide (Temodar)
  11. Trametinib (Mekinist)
  12. Vemurafenib (Zelboraf)
  • Combination Chemotherapy
  1. Paclitaxel nanoparticle albumin-bound + Bevacizumab + Carboplatin (ABC)
  2. Carboplatin + Paclitaxel
  3. Carboplatin + Paclitaxel + nanoparticle albumin-bound
  4. Carboplatin + Paclitaxel +, Sorafenib
  5. Cisplatin + Dacarbazine ± Carmustine
  6. Cisplatin + Dacarbazine + IL-2 + IFN alfa-2b ± Carmustine
  7. Cisplatin + Paclitaxel + Dacarbazine
  8. Cisplatin + Vinblastine + Dacarbazine
  9. Cisplatin + Vinblastine + Dacarbazine + IL-2 + IFN alfa-2b (sequential biochemotherapy)
  10. Temozolomide + Bevacizumab
  11. Dabrafenib + Trametinib
  12. Ipilimumab + Dacarbazine
  13. Ipilimumab + Nivolumab
  14. Binimetinib + Encorafenib

References

  1. 1.0 1.1 Peter Yang and Jeremy Warner. Melanoma. Hemonc.org. Accessed on August 21, 2015. http://hemonc.org/wiki/Melanoma

Linked-in.jpg